{"name":"LiNing","slug":"lining","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"docetaxel plus oxaliplatin and capecitabine","genericName":"docetaxel plus oxaliplatin and capecitabine","slug":"docetaxel-plus-oxaliplatin-and-capecitabine","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"oxaliplatin plus capecitabine","genericName":"oxaliplatin plus capecitabine","slug":"oxaliplatin-plus-capecitabine","indication":"Metastatic colorectal cancer","status":"marketed"}]}],"pipeline":[{"name":"docetaxel plus oxaliplatin and capecitabine","genericName":"docetaxel plus oxaliplatin and capecitabine","slug":"docetaxel-plus-oxaliplatin-and-capecitabine","phase":"phase_3","mechanism":"Docetaxel works by inhibiting microtubule dynamics, while oxaliplatin induces DNA damage and interstrand crosslinks, and capecitabine is a thymidylate synthase inhibitor.","indications":["Metastatic colorectal cancer","Adjuvant treatment of stage III colon cancer"],"catalyst":""},{"name":"oxaliplatin plus capecitabine","genericName":"oxaliplatin plus capecitabine","slug":"oxaliplatin-plus-capecitabine","phase":"marketed","mechanism":"Oxaliplatin and capecitabine work together as a chemotherapy combination where oxaliplatin cross-links DNA to prevent replication while capecitabine is converted to fluorouracil to inhibit thymidylate synthase and disrupt nucleotide synthesis.","indications":["Metastatic colorectal cancer","Gastric cancer","Pancreatic cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOSklabktlRmxDbGJpejBFZmw0RlFSM1FFcW45c2dBWFh3LVA2RkxBWTZuMFBpdFc3SVBiUzF3YjJBZFRQbGV5Q0tib1BVLU5jQ2NTZVlYTTlCajhaWE1fdVVlVklDZTZ0Q1RrVzMtMnkyeDQ2WUNHUzk1ZDZaLW90c3RxaTkyU3dSc0RfM0x1WUhldUV3dXdBR2xpYzYwWUoxejN2anZnQTFOelB6a21zQzBrcXY0eWt6YlAzeExSQi1PR0dxMUNjcUtzN0prbGJYS3RXVEp1WVhodw?oc=5","date":"2026-04-08","type":"pipeline","source":"IndexBox","summary":"World PTFE and PFA Lined Diaphragm Valves - Market Analysis, Forecast, Size, Trends and Insights - IndexBox","headline":"World PTFE and PFA Lined Diaphragm Valves - Market Analysis, Forecast, Size, Trends and Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNY0ZsREs3UjQzX1hBdUpMUTVtZHFJVWQ5RGFXbEtjNFhOVk95TzVQTFo4TXo5WHNXNVJPNlpmb3NkSkxmdFRwbEFWeUNPOTlJOUM5cXI3Tl9URi1kYjBiR3U3ZGVaU0JfRnFBR0NYU3lXZVF5WElSbTEyQktBbkhlTWV3TzI0RHFRUXdoOXdNbmVMR0oyeGJzVDdaZHFpLTVjSHZIel9aWm1qWHp2Z0RwTjRYTV8?oc=5","date":"2026-03-05","type":"pipeline","source":"AgFunderNews","summary":"With crop protection at a crossroads, it’s time for big ag to embrace its big pharma moment - AgFunderNews","headline":"With crop protection at a crossroads, it’s time for big ag to embrace its big pharma moment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-23","type":"earnings","source":"NDTV Profit","summary":"Silver Lining Amid Tariff Turmoil — These Three Sectors Are Shielded From Trump's New 15% Duty - NDTV Profit","headline":"Silver Lining Amid Tariff Turmoil — These Three Sectors Are Shielded From Trump's New 15% Duty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNSDI3WDBuZDRLYnZHamFCdHl2MEk1V2VsVkJNTEtocktqeldLQUdndW80UTVBQWlmcVZLemh5YWZqNi1wRjFGdE9qYTdOaE9YS1BreThNbmk0cGI0cFg2Qmd6RkxqelN3TGhNQUdfa0FiQnRwNGJWWGw1alp4RGZKNy0xWVJXOXJxYzFkeWVsVExPZEhLbkFiTnhpRUZyX185UXMyOWxINFZmOGlTd3JFSzZrMTZ5UQ?oc=5","date":"2026-02-03","type":"pipeline","source":"Fierce Pharma","summary":"Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade - Fierce Pharma","headline":"Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBRakVxdmhlcE85NEp4N0Nfd1g4TDBHZUZSSUtrUGJDZEI0UmlpNE9OS0RqOTkzTFlmUTlVcFByLXhGSzZ5cGxpQjJQQmVvWTVfamJjTDUtcXFyYTVtYms0bzY3LXAwenYwY1lCZU9IWUtodFZMM2NrNUVB?oc=5","date":"2025-12-02","type":"pipeline","source":"Investor's Business Daily","summary":"This Biotech Is On A Triple-Digit Run, And Shows No Signs Of Slowing - Investor's Business Daily","headline":"This Biotech Is On A Triple-Digit Run, And Shows No Signs Of Slowing - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPbWdGWXB5VHZBWVNaeW0zVzJOMjVqTnY5dWR5QlVnM1VnZ2ZpaWpNSDgyU2xjd1h1N0pUS2lhNFlWVzdfY2xic1liNWFUc1A0cHNEZWNqM0gzWjRQanllU29MNzlLQlZjS1RwZXRRTHRqSHpqNm9JSTY5WFhhN1BITEZXeHRIYldrbFJJaEd6b0FnLThvMDd2bUg2NVZEQktRQUU0QzFB?oc=5","date":"2025-06-18","type":"pipeline","source":"Politico","summary":"Pharma’s silver lining: A tax break - Politico","headline":"Pharma’s silver lining: A tax break","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQZjBCcXpGOWNZN2xjc0ZKSXpleU83bERTY204ZjhpZ0FHa3NFbXhjVl9HbzhFdlY0aVEyTFlrT2dhWlBFSGJwajhpbkVQRnpkaDVyMDVxYjc0Q0Z0Y29OcXNySDh4dFVVUlV2Z2c1RzVrWFYxQ004d2k2V3pKSjREZmlzcHo3UTZTdVlSV2lYcW9QM1Rvc2FIMXlXYzR6dzVRZHpEZ1Nn?oc=5","date":"2025-05-02","type":"regulatory","source":"Fierce Pharma","summary":"AstraZeneca's Breztri aces 2 asthma trials, lining it up for label expansion - Fierce Pharma","headline":"AstraZeneca's Breztri aces 2 asthma trials, lining it up for label expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPWVhhdkMwOXBBLXRpZTl1N0NwWlFrOE5MWE9VTXpUa3pDQ2JUWTcyUVpmVnQ4R2dRdExmdUlqQXJRNk9jMzB2ZjJxNnRKM2pmMDZubEhnakx0WnBvX3NoMnhmTjlEUTdlb3EwYXprQ1pwdk9yVG02WGVSR1A4cEpGN3F3VHdEeVkxQnJZQS05SQ?oc=5","date":"2025-02-17","type":"trial","source":"pharmaphorum","summary":"Istesso backer sees silver lining in failed arthritis trial - pharmaphorum","headline":"Istesso backer sees silver lining in failed arthritis trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQZHpUMWFQbmZCd1B6ZFR2ck5SUkJYd3RiQzNDYVY5VUhxYVdmUTdYNDRhVWg0MzIxZk1DYjR5V0o0c1dETVg2cERvYXczY0JQdkFHYm1lWDNRRE80d0FFYVJZRmRIRUN4MXZROWRJTXBKczVzRTZKdC12R1lNTjlXLWdmSzZrU04zTUZndDh2SnE5UQ?oc=5","date":"2023-05-25","type":"trial","source":"BioPharma Dive","summary":"Annexon claims a silver lining in failed eye drug study - BioPharma Dive","headline":"Annexon claims a silver lining in failed eye drug study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQVEZ0TmRBeVpDdHFUOHQxdU5aajRfMTdEM3NiY3dvSlB2ZmVHRVZQdXhZLXpmYmg4d3pYWVV6bUtSQnAzejhKcmZjVE9pbkpwanNyS21fa0JQVExkdXJXT1AyeUdYMWpSN0dLWllzaUQxWmdEcWkyYjZqR1Y5RlRDcldpY09vbllfTGdzdWxQeGlZUQ?oc=5","date":"2022-03-02","type":"trial","source":"pharmaphorum","summary":"Pfizer's seeks silver lining in failed C. diff vaccine trial - pharmaphorum","headline":"Pfizer's seeks silver lining in failed C. diff vaccine trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNNTJfZWk1ZlhmUElDVGRhR3JvYjdIbXVVa1hrYWs0WkxOODNmYVlEd3JTRFdZbW91WTJLM2VTTGVjZ0VMUzVnQ0NkZjJESG5zbmtBWm5uOTJFdUdVNkVIZWpiZDlYV2pRYUVuX2t5cE5WR1ZTUHlpV2xFLXMtQkdWNXQya1J1Q2c?oc=5","date":"2022-01-13","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Pharma R&D ROI hits highest level since 2014 - drugdiscoverytrends.com","headline":"Pharma R&D ROI hits highest level since 2014","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9zRXZqdmZJVFhzRHdYRmllRjFMUkdSYktaSnR1NGRtZ2hZRE5PekZMTDh6emJQQ0lKQ0tZZHZuVXE5dFJUVGtIVWlWVmgwSGVMVzdua25iNXNyQk1mS19Oemltd1lPb1FSbmZlUWhXRUdscGcwYVRJWg?oc=5","date":"2017-11-13","type":"pipeline","source":"National Association of Counties","summary":"Over 100 counties lining up to sue big pharma - National Association of Counties","headline":"Over 100 counties lining up to sue big pharma","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}